Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate

Retinol remains a cornerstone ingredient in topical antiaging therapy because of its well-established effects on skin renewal, acne, and photoaging. However, its widespread use is often limited by poor chemical stability, sensitivity to heat and light, and the risk of irritation.¹ Investigators recently evaluated bakuchiol ferulate (BF), a newly synthesized compound that combines bakuchiol with a ferulic acid analog, to determine whether it could provide retinol-like activity while improving stability and tolerability.² The study compared BF with retinol (ROL), bakuchiol (BKU), and ferulic acid (FA) using laboratory testing, cell-based assays, a 14-day cumulative irritation study in human volunteers, and transcriptomic analysis in human dermal fibroblasts.

Chemical Stability Under Light and Heat

One of the most notable findings was BF's superior chemical stability. High-performance liquid chromatography analyses conducted over 90 days showed that BF maintained greater stability than retinol under both light exposure and elevated temperatures. Under light conditions, BF retained more than 86% of its original concentration after 90 days, whereas retinol retained only about 6%. Under accelerated thermal conditions at 48 °C, BF showed virtually no degradation throughout the study period, while retinol retention declined to approximately 8%. These findings suggest that molecular hybridization improved stability beyond that of either parent compound.

Photo-Reactivity and Phototoxicity

The researchers also examined photo-reactivity and phototoxicity. Electron paramagnetic resonance spectroscopy demonstrated that BF generated very low levels of superoxide radicals following light exposure, comparable to ferulic acid and substantially lower than retinol or bakuchiol. Phototoxicity was further evaluated using the OECD 432 3T3 neutral red uptake assay. BF produced a photoirritation factor (PIF) of 1.14, classifying it as non-phototoxic. Bakuchiol and ferulic acid were also classified as non-phototoxic, while retinol exceeded the threshold for phototoxicity with a PIF of 5.64.

Additional reactive oxygen species testing supported these findings. Across both keratinocyte and fibroblast models exposed to ultraviolet radiation, BF consistently generated lower levels of singlet oxygen and superoxide anions than retinol or bakuchiol. The investigators concluded that BF demonstrated minimal UV-induced oxidative stress, further supporting its favorable photostability profile.

Cell Viability, Cytotoxicity, and Skin Penetration

Cell viability studies also suggested an improved safety profile. Cytotoxicity was evaluated in HaCaT keratinocytes and NIH/3T3 fibroblasts using CCK-8 assays across a range of concentrations. BF maintained greater than 80% cell viability at substantially higher concentrations than retinol or bakuchiol, indicating lower cytotoxicity in vitro. The study also assessed skin penetration using excised miniature pig skin. BF demonstrated concentration-dependent permeation through the skin, with increasing delivery observed as formulation strength increased. Dermal retention appeared to plateau between the 0.5% and 1% formulations, suggesting that higher concentrations may not substantially increase skin deposition.

Human Tolerability and Transcriptomic Analysis

Human tolerability was evaluated in a 14-day cumulative patch test involving healthy adult volunteers. Multiple concentrations of BF ranging from 0.05% to 1.0% were compared with retinol concentrations of 0.05%, 0.1%, and 0.3%. All BF formulations were classified as nonirritating based on their Mean Cumulative Irritancy Index (MCII), including the highest 1.0% concentration. In contrast, 0.3% retinol was classified as slightly irritating, while lower retinol concentrations remained nonirritating.

To determine whether BF retains retinoid-like biological activity, investigators performed RNA sequencing in human dermal fibroblasts. Transcriptomic analysis demonstrated strong similarity between BF and retinol, with a Pearson correlation coefficient of 0.89. Both compounds upregulated genes involved in cell cycle regulation, DNA replication, homologous recombination, and DNA repair, pathways associated with retinoid-mediated skin renewal.

Importantly, BF differed from retinol in several molecular signatures linked to adverse effects. Retinol uniquely upregulated pathways associated with apoptosis, p53 signaling, inflammatory cytokine signaling, and necroptosis, whereas these pathways were not enriched in BF-treated cells. Instead, BF uniquely enhanced pathways related to motor protein activity and cell cycle regulation, suggesting preservation of beneficial retinoid-like activity without activating several pathways associated with inflammation or cell death.

Conclusion and Future Directions

The investigators concluded that BF functions as a retinol analog with enhanced chemical stability, reduced phototoxicity, and improved skin tolerability while maintaining many of retinol's beneficial gene expression patterns. They noted, however, that transcriptomic similarity alone does not establish equivalent clinical efficacy. Additional long-term in vivo studies and clinical trials evaluating outcomes such as collagen production and wrinkle reduction will be necessary to confirm BF's therapeutic potential in cosmetic and dermatologic applications.

References

1. Cheong KA, Kim HJ, Kim JY, et al. Retinoic acid and hydroquinone induce inverse expression patterns on cornified envelope-associated proteins: implication in skin irritation. J Dermatol Sci. 2014;76(2):112-119. doi:10.1016/j.jdermsci.2014.08.003

2. Zhong J, Yan Y, Zhao N, et al. Bakuchiol Ferulate: A Novel Functional Retinol Analog With Enhanced Photostability and Reduced Phototoxicity for Cosmetic Applications. Journal of Cosmetic Dermatology. 25, no. 7 (2026): e71067, doi:10.1111/jocd.71067